- Home
- MYNZ vs CVKD Comparison
MYNZ vs CVKD Comparison
Compare MYNZ & CVKD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MYNZ | CVKD |
|---|---|---|
| Founded | 2021 | 2022 |
| Country | Germany | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medicinal Chemicals and Botanical Products |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.6M | 20.7M |
| IPO Year | 2021 | 2023 |
Fundamental Metrics
Financial Performance| Metric | MYNZ | CVKD |
|---|---|---|
| Price | $1.19 | $6.96 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | $14.00 | ★ $32.00 |
| AVG Volume (30 Days) | ★ 449.2K | 54.3K |
| Earning Date | 09-26-2025 | 03-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $659,935.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $5.03 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.92 | $6.42 |
| 52 Week High | $8.20 | $22.90 |
Technical Indicators
Market Signals| Indicator | MYNZ | CVKD |
|---|---|---|
| Relative Strength Index (RSI) | 50.80 | 39.22 |
| Support Level | $1.08 | $6.55 |
| Resistance Level | $1.20 | $8.79 |
| Average True Range (ATR) | 0.12 | 0.58 |
| MACD | -0.00 | 0.10 |
| Stochastic Oscillator | 26.17 | 24.79 |
Price Performance
Historical ComparisonAbout MYNZ Mainz Biomed N.V.
Mainz Biomed NV develops market-ready molecular genetic diagnostic solutions for life-threatening conditions. The company's flagship product is ColoAlert, is an accurate, non-invasive and easy-to-use, early-detection diagnostic test for colorectal cancer based on real-time Polymerase Chain Reaction-based (PCR) multiplex detection of molecular-genetic biomarkers in stool samples. The company operates in one operating segment, genetic diagnostic testing.
About CVKD Cadrenal Therapeutics Inc.
Cadrenal Therapeutics Inc is developing tecarfarin, its drug candidate, for unmet needs in anticoagulation therapy. Tecarfarin is a late-stage novel oral and reversible anticoagulant (blood thinner) designed to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation.